Wipro GE Healthcare Private Limited
Ground, Magnolia, Kalyani Platina,
EPIP Zone, Whitefield Road,
Brookefield, Kundalahalli, Bengaluru,
Karnataka, 560066
www.wiproge.com

Annexure – C
REPORT ON CORPORATE SOCIAL RESPONSIBILITY (CSR)

1. **A brief outline of the Company's CSR policy including overview of the projects or programs proposed to be undertaken and a reference to the CSR policy and projects or programs.**

Mission Statement for CSR for the Company-

We are at work for a healthier society, addressing some of South Asia's healthcare challenges by supplementing Government and societal efforts. Our endeavor is to improve the quality of health and living of those in need by way of augmenting healthcare infrastructure and capability building, patient support programs, Environment sustenance and emergency response during pandemics and natural disasters.

In line with the CSR Policy adopted by the Board of Directors, the CSR Committee for the financial year 2024-25 focused on the following broad areas: -

S.NO	Particulars	CSR Activities Covered
1	Capability Building for Healthcare eco-systems	**Employment enhancing vocational skills:** • Enhance the capacity of the healthcare workers at IPHLs/CHCs/PHCs and UPHC effectively provide essential services. • **Women's MTech Scholarship:** The Program encourages women belonging to EWS by awarding (stipend)scholarship to pursue M.Tech program This scholarship program specifically to help support their journey in the technology sector.
2	Healthcare Pivots	• **Low-income cancer patients:-** Through Navya's affiliations with Tata Memorial Hospital and the National cancer Grid, we provide low income cancer patients with an opportunity to a second opinion via online access to Onco Experts on the national Cancer Grid and offer guidance to follow through with the treatment plan • **Substantiating the Medical treatment of underprivileged children suffering from Congenital Heart Defects .**
3	Core Healthcare Infrastructure	• **Integrated Diagnostics Labs and robust community surveillance mechanisms-** To provide technical and operational assistance for setting up of integrated diagnostic labs, guided by a human centered design approach – to Odisha with PATH-CHRI leading to strengthening universal health coverage and health security. • **Strengthening Government Community Health Centres Program** infrastructure and diagnostic facilities
4	Environment	• **Upgradation of the Environment around Kadugodi-Dinnur Area of Bangalore, including road laying accompanying Public infrastructure** To revitalize essential infrastructure vital for ensuring safe mobility, improved access, reduction in accidents and enhancing overall public well-being by building road and amenities upgradation at a village in an Industrial area.

Sensitivity: Internal & Restricted

2. **Composition of the CSR Committee**

The CSR Committee comprises of the following member directors:

Sl.NO	Name of Director	Designation/ Nature of Directorship	No of Meeting of CSR Committee held during the year	Number of meetings of CSR Committee attended during the year
1	Mr. Suresh Chandra Senapaty	Director/Chairman of CSR Committee	3 (Three)	3
2	Mr. Chaitanya Sarawate	Managing Director/Member of CSR Committee	3 (Three)	3
3	Mr. Kenneth Stacherski	Director/Member CSR Committee	3 (Three)	3

Mr. Suresh Senapaty was unanimously elected as Chairman of all the CSR Committee Meetings held during the Financial Year 2024-25.

3. **Provide the web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the Board are disclosed on the website of the Company.-**

i. The composition of the CSR committee is available on our website at- https://www.gehealthcare.in/-/jssmedia/global/india/corporate-governance/constitution-of-csr-committee--wge.pdf.

ii. The Committee, with the approval of the Board, has adopted the CSR Policy as required under Section 135 of the Companies Act, 2013. The CSR Policy of the Company is available on our website at- https://www.gehealthcare.in/-/jssmedia/global/india/corporate-governance/wipro-ge-csr-policy.pdf

iii. CSR projects approved by the Board are disclosed on the website of the Company at- https://www. https://www.gehealthcare.in/-/jssmedia/global/india/corporate-governance/csr-projects-of-the-company-for-fy-2022-23.pdf

4. **Provide the executive summary along with web-link(s) of Impact Assessment of CSR Projects carried out in pursuance of sub-rule (3) of rule 8, if applicable. –** The Company takes cognizance of sub-rule (3) of Rule 8 of the Companies (Corporate Social Responsibility Policy) Amendment Rules, 2021 ("CSR Amendment Rules") and as per threshold limits specified under the same, the Rules are not applicable as on date of this Report. The Company is in the process of voluntarily conducting impact assessments through independent agencies to screen and evaluate select CSR programs.

5. **Net Profits calculations and Prescribed CSR Expenditure.**

a) **Average Net Profit of the Company as per Section 135 (5) of the Companies Act, 2013 –** The average net profits of the Company during the last three years as per Section 198 is **INR 52,957 lakhs**

b) Two percent of average net profit of the Company as per Section 135(5):- **INR 1059 lakhs**

c) Surplus arising out of the CSR projects or programmes or activities of the previous financial years.- Nil.

d) Amount required to be set off for the financial year, if any:- **INR (17) lakhs**

e) Total CSR obligation for the financial year (7a+7b-7c).- **INR 1042 Lakhs**

f) Total CSR allocated for the financial year – **INR 1042 Lakhs**

Sensitivity: Internal & Restricted

6.

a) **Amount spent on CSR Projects (both Ongoing Projects and other than Ongoing projects):- INR 414 lakhs**
b) **Amount spent in Administrative Overheads- INR 52 Lakhs**
c) **Amount spent on Impact Assessment, if applicable- Not Applicable**
d) **Total amount spent for the Financial Year (8b+8c+8d+8e) – INR 466 Lakhs**
e) **CSR Amount spent or unspent for the Financial Year:-**

Total Amount Spent for the Financial Year (In Lakhs Rs)*	**Amount Unspent (in Lakhs Rs)**				
	Total Amount Transferred to Unspent CSR Account as per Section 135(6)**		**Amount transferred to any fund specified under Schedule VII as per second proviso to section 135(5).**		
	Amount in Lakhs	Date of Transfer	Name of the Fund	Amount	Date of Transfer
466*	576	Refer Note.	Nil	Nil	Nil

Note:- * Includes a sum of Rs 52 Lakhs incurred towards administration overheads.
**The unspent amount has been transferred to unspent CSR account within 30 days from the end of the financial year, in accordance with the Companies Act, 2013 read with the CSR Amendment Rules 2021.

f) Excess amount for set-off, if any:-

Sl. No.	**Particular**	**Amount (In INR lacs)**
(i)	Two percent of average net profit of the Company as per sub-section (5) of section 135 Company allocated CSR amount	**1059**
(ii)	Total amount spent for the Financial Year	**466**
(iii)	Excess amount spent for the Financial Year [(ii)-(i)]	Nil
(iv)	Surplus arising out of the CSR projects or programmes or activities of the previous Financial Years, if any	**17**
(v)	(v) Amount available for set off in succeeding Financial Years [(iii)-(iv)]	Nil

Sensitivity: Internal & Restricted

g) Details of CSR amount spent against on the CSR Ongoing Projects for the Financial Year 24-25:-

1.	2.	3.	4.	5.		6.	7.	8.	9.	10.	11.	
Sr. No.	Name of the Project	Item from the list of activities in Schedule VII to the Act.	Local area (Yes/No.)	Location of the Project - State/District		Project Duration (in years) *	Amount allocated for the Projects in FY 24-25 (Rs In lakhs)	Amount spent in the current financial year FY 24-25: (Rs In lakhs)	Amount transferred to Unspent CSR Account for the project as per Section 135(6) (in lakhs.).	Mode of Implementation – Direct (Yes/No)	Mode of Implementation – through Implementation Agency	
				State	District						Name	CSR Reg No
1.	Women's MTech Scholarship (2 years program) – Support for Year 1	(i)	Yes	KAR	Bangalore	3	12	4	8	No	IISc/Collective Good Foundation	CSR00001648
2.	Low-income patients assisted in small towns/rural areas with Navya' s Low-cost Online Service to scale access to Experts and treatment scheduling	(i)/(ix)	No	A.P.	Visakhapatnam, Kakinada & Tanuku	3	127	63	64	No	Navya/Collective Good Foundation	CSR00001648
3.	Primary Health Care Upgradation	(i)/(ix)	Yes	Karnataka	Raichur	1	100	100	0	No	Bharat Cares /Collective Good Foundation	CSR00001648

Sensitivity: Internal & Restricted

4.	Integrated Diagnostics Labs and robust community surveillance mechanisms	(i)/(ix)	No	Odisha	Bolangir, Gajapati, Kandhamal, Kalahandi, Nabarangpur & Sambalpur	3	269	Nil	269	No	PATH/ Collective Good Foundation	CSR00001648
5.	Kadugodi Road Project	(i)/(ix)	Yes	KAR	Bangalore	3	245	11	235	No	Ground Reality	CSR00005265
6.	Contribution of Diagnostic Equip to Public Health Facilities	(i)/(ix)	No	MH/ Manipur	Nandurbar, Satara, Nagpur in MH & Manipur state	3	211	211	0	No	Path/Collective Good Foundation	CSR00001648
7.	Medical Treatment for underprivileged Children from the age group of 0-18 years suffering CHD	(i)/(ix)	No	Pan India		1	26	26	0	No	Genesis Foundation/ Collective Good Foundation	CSR00001648
8	Mobile clinic van in Dimahisao	(i)/(ix)	No	Assam	Dimaisao	1	0.3	0.3	0	No	Cachar/Collective Good Foundation	CSR00001648
9	Admin Expenses-5% of NP						52	52	0			
Total CSR allocated							**1042**	**466**	**576**			

*These are 'ongoing projects' as defined in the CSR Amendment Rules. The years mentioned include the financial year in which the project was commenced.

7.

a) **Details of Unspent CSR amount for the preceding three financial years:**

S.NO	Preceding Financial year	Amount transferred to Unspent CSR Account under Section 135(6) In Rs in lakhs	Balance Amount in Unspent CSR Account under sub-section (6) of section 135Rs in lakhs	Amount Spent in the Reporting Financial Year 24-25 Rs in lakhs	Amount transferred to any fund specified under schedule VII as per Sec 135(6), if any (6)		Amount remaining to be spent in succeeding financial year	Deficiency, if any
(1)	(2)	(3)	(4)	(5)	Amount	Date of Transfer	(7)	(8)
1	**FY 2022-23**							
A	Women's MTech Scholarship (2 years program) – Support for Year 1	11.6	0.6	1.5	Nil	NA	Nil	NA
B	Integrated Diagnostics Labs and robust community surveillance mechanisms	274	Nil	60	Nil	NA	Nil	NA
	FY 2023-24							
1	Employment enhancing vocational skills- Nursing aid / Bedside assistant Program	29	Nil	29	Nil	Nil	Nil	Nil
2	Women's MTech Scholarship (2 years program) – Support for Year 1	16	4	12				
3	PHC Up gradation	153	7	146				
4	Integrated Diagnostics Labs and robust community surveillance mechanisms	189	Nil	189	Nil	Nil	Nil	Nil
5	Kadugodi Road Project which was re-	59	Nil	59	Nil	Nil	Nil	Nil

	purposed by the Board to Contribution of Diagnostic Equip to Public Health Facilities at Maharastra and Manipur							

8. **In case of creation or acquisition of capital asset, furnish the details relating to the asset so created or acquired through CSR spent in the financial year(asset-wise details).- No capital asset was created / acquired for fiscal 2021 through CSR spend.**

a) Date of creation or acquisition of the capital asset(s).-NA
b) Amount of CSR spent for creation or acquisition of capital asset.- NA
c) Details of the entity or public authority or beneficiary under whose name such capital asset is registered, their address etc.- NA
d) Provide details of the capital asset(s) created or acquired (including complete address and location of the capital asset).- NA

9. **Specify the reason(s), if the Company has failed to spend two per cent of the average net profit as per section 135(5)-**

During Financial Year 2024-25, the Company has spent Rs. 466 lakhs on various projects and transferred Rs. 576 lakhs to the Unspent CSR Account of the Company as on April 30,2025 against one of the "Ongoing Project" i.e. as detailed below with the reasons specified there in. The entire amount of Rs. 576 lakhs has been transferred from Unspent CSR Account of the Company shall be completed in accordance with the CSR Amendment Rules.

1.	2.	3.	4.	5.	6.	7.		Reasons for not Spending
Sr. No.	Name of the Project	Project Duration (in years) *	Amount allocated for the Projects in FY 24-25 (Rs In lakhs)	Amount spent in the current financial year FY 24-25: (Rs In lakhs)	Amount transferred to Unspent CSR Account for the project as per Section 135(6) (in lakhs.).	Mode of Implementation – through Implementation Agency Name	CSR Reg No**	
1	Low-income patients assisted in small towns/rural areas with Navya' s Low-cost Online Service to scale access to Experts and treatment scheduling	3	127	63	64	Indirect-Collective Good Foundation	CSR00001648	This is an ongoing project, the funds were transferred to the unspent account and shall be spent as per the project timelines in the agreement.

2	Women's MTech Scholarship	3	12	4	8	Indirect-Collective Good Foundation	CSR00001648	This is an ongoing project, the funds were transferred to the unspent account and shall be spent as per the project timelines in the agreement and academic year.
3	Integrated Diagnostics Labs and robust community surveillance mechanisms	3	269	Nil	269	Indirect-Collective Good Foundation	CSR00001648	This is an ongoing project, the funds were transferred to the unspent account and shall be spent as per the project timelines in the agreement and academic year.
4	Kadugodi Road Project	3	245	11	235	Indirect – Ground Reality	CSR00005265	Project execution delay due to awaiting approval from Bruhath Bengaluru Municipal Corporation(BBMP) for building the road and other infrastructures.

For WIPRO GE HEALTHCARE PRIVATE LIMITED

Azim H. Premji
Chairman
DIN-00234280

Suresh Senapaty
Chairman CSR Committee
DIN-00018711

Chaitanya Sarawate
Managing Director
DIN- 10041335

WIPRO GE HEALTHCARE PRIVATE LIMITED BANGALORE

Place: Bangalore
Date: July 28, 2025

Wipro GE Healthcare Private Limited
Ground, Magnolia, Kalyani Platina,
EPIP Zone, Whitefield Road,
Brookefield, Kundalahalli, Bengaluru,
Karnataka, 560066
www.wiproge.com

Annexure- I

Form AOC-I

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

Statement containing salient features of the financial statement of subsidiaries/associate companies/joint ventures

Part "A": Subsidiaries

(Information in respect of each subsidiary to be presented with amounts in BDT/LKR / INR)

1. Sl. No.	1	2	3
2. Name of the subsidiary	GE HEALTHCARE BANGLADESH LIMITED	GENERAL ELECTRIC HEALTHCARE LANKA (Private) Limited	Wipro GE Medical Device Manufacturing Private Limited
3. Reporting period for the subsidiary concerned, if different from the holding Company's reporting period	1 July 2023 to 30 June 2024		
4. Reporting currency and Exchange rate as on the last date of the relevant Financial year in the case of foreign subsidiaries.	Reporting currency - BDT Exchange rate as on last date of financial year – 0.76 BDT = 1.00 INR	Reporting currency – LKR Exchange rate as on last date of financial year – 0.26 LKR = 1.00 INR	Reporting currency – INR
5. Share capital	(16,64,31,778)	(25,81,500)	(2,00,10,000)
6. Reserves & surplus	(10,28,64,940)	(2,67,79,829)	(65,56,93,542)
7. Total assets	1,49,67,18,257	2,93,61,329	2,29,05,63,660
8. Total Liabilities	(1,22,74,21,539)	Nil	(1,61,48,60,118)
9. Investments	Nil	Nil	Nil
10. Turnover	1,94,99,71,864	Nil	4,60,94,94,856
11. Profit / (Loss) before taxation	11,67,68,357	(26,13,804)	37,01,28,177
12. Provision for taxation	(7,99,58,001)	Nil	(7,06,73,709)
13. Profit/(Loss) after taxation	3,68,10,356	(26,13,804	29,94,54,468
14. Proposed Dividend	-	-	-
15. % of shareholding	100%	100%	100%

Notes: The following information shall be furnished at the end of the statement:

1. Names of subsidiaries which are yet to commence operations	NIL
2. Names of subsidiaries which have been liquidated or sold during the year.	Not Applicable

Sensitivity: Internal & Restricted

Part "B": Associates and Joint Ventures

Statement pursuant to Section 129 (3) of the Companies Act, 2013 related to Associate Companies and Joint Ventures

Name of Associates/Joint Ventures	Genworks Health Private Limited	Clean Max Dos Private Limited
1. Latest audited Balance Sheet Date	31st March 2023	31st March 2025
2. Shares of Associate/Joint Ventures held by the Company on the year end		
Nos.	1,006,927	26,790
Amount of Investment in Associates/Joint Venture	234,727,000	15,999,450
Extend of Holding %	15.7%	24.2%
3. Description of how there is significant influence	Participation in major decisions over key areas/ policies without any control over these policies.	There is no significant influence.
4. Reason why the associate/joint venture is not consolidated	Associate investment would not constitute controlling interest.	The investment would not constitute controlling interest.
5. Net worth attributable to Shareholding as per latest audited Balance Sheet	INR 1,428 Lacs	INR 697 Lacs
6. Profit / (Loss) for the year	INR (4,037) Lacs	INR 38 Lacs
i. Considered in Consolidation	INR 818 Lacs*	Not Applicable
i. Not Considered in Consolidation	Not Applicable	Not Applicable

**Reversal of loss pick up as impairment considered in the Standalone Financials for the year 2024-25.*

1. Names of associates or joint ventures which are yet to commence operations.	Nil
2. Names of associates or joint ventures which have been liquidated or sold during the year.	Nil

Sensitivity: Internal & Restricted

For WIPRO GE HEALTHCARE PRIVATE LIMITED

A.H. Premji
Chairman
DIN: 00234280

S.C. Senapaty
Director
DIN: 00018711

Elie Georges Chaillot
Director
DIN: 09540431

WIPRO GE HEALTHCARE PRIVATE LIMITED · BANGALORE

Mr. Chaitanya Sarawate
Managing Director
DIN: 10041335

Rahul Cordeiro
Chief Financial Officer
PAN-AFVPC7972H

Manjunath Hegde
Company Secretary
ACS-28166

Place: Bangalore
Date- July 28, 2025

Sensitivity: Internal & Restricted